A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Study Identifier:

382-201-00035

ClinicalTrials.gov Identifier:

NCT06894212

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

844-687-8522 or [email protected]

Recruiting

Subscribe to Updates

Study Details

Medical Condition

Schizophrenia

Study Drug

Drug: SEP-363856

Date

Feb 2025 - Apr 2028

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 18 - 65 Years

Requirements Information

Protocol Summary

This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia

Study Locations

Location

Status

Location

Clinical Research Site # 145

Bentonville, Arkansas, United States, 72712

Status

Recruiting

Location

Clinical Research Site # 138

Rogers, Arkansas, United States, 72758

Status

Recruiting

Location

Clinical Research Site # 136

Riverside, California, United States, 92506

Status

Recruiting

Location

Clinical Research Site # 126

San Diego, California, United States, 92123

Status

Recruiting

Location

Clinical Research Site # 130

Sherman Oaks, California, United States, 91403

Status

Recruiting

Location

Clinical Research Site # 125

Miami Lakes, Florida, United States, 33016

Status

Recruiting